http://biz.yahoo.com/prnews/980902/md_guilfor_2.html
Wednesday September 2, 10:10 am Eastern Time
Company Press Release
SOURCE: Guilford Pharmaceuticals Inc.
Guilford Announces Receipt of Broad New
Patents In FKBP-Neuroimmunophilin Ligand Program,
Compounds That Promote Nerve Growth
BALTIMORE, Sept. 2 /PRNewswire/ -- Guilford Pharmaceuticals Inc.
today announced that the Company has been issued four new U.S. patents
in its
FKBP-neuroimmunophilin ligand neurotrophic program, including broad
methods for treating neurological diseases with immunophilin ligands.
These patents relate to compounds which are orally-active small
molecules that cross the blood-brain-barrier and induce regeneration and
protection of neuronal cells. Guilford's compounds have demonstrated
activity in a number of animal models of Parkinson's disease and other
acute and chronic neurological diseases and conditions. Results from
some of these studies have been published in The Proceedings of the
National Academy of Sciences and Nature Medicine, and presented at the
1997 meeting of the Society for Neuroscience.
The newly issued patents are as follows:
U.S. Patent No. 5,795,908, ``Small Molecule Inhibitors of Rotamase
Enzyme Activity``, claims methods of using a broad class of small
molecule
non-immunosuppressive FKBP ligands to treat neurological disorders
(including Alzheimer's disease, PARKINSON'S disease, amyotrophic lateral
sclerosis (ALS), and peripheral neuropathies), promote neuronal
regeneration
and growth, and prevent neurodegeneration.
U.S. Patent No. 5,798,355, ``Inhibitors of Rotamase Enzyme
Activity'', claims methods of using a broad class of
non-immunosuppressive FKBP ligands, including a number of compounds
previously published in
the patent and scientific literature, to treat neurological
disorders (including Alzheimer's Disease, Parkinson's Disease,
peripheral neuropathies, stroke, brain and spinal cord injuries, and
ALS), stimulate growth of damaged peripheral nerves, and promote
neuronal regeneration and growth.
U.S. Patent No. 5,801,197, ``Rotamase Enzyme Activity Inhibitors'',
claims methods of using certain non-immunosuppressive FKBP ligands which
have been previously published in the patent literature, to stimulate
the growth of damaged nerves.
U.S. Patent No. 5,801,187, ``Heterocyclic Esters and Amides'',
claims novel non-immunosuppressive compounds (compositions of matter)
designed
by Guilford and their neurotrophic and neurological uses, including
for the treatment of Alzheimer's Disease, Parkinson's Disease,
peripheral neuropathies, stroke, brain and spinal cord injuries, and
ALS.
Additional scientific presentations are planned for later this
year, at the Cambridge Healthtech Institute meeting on Acute Neuronal
Injury: New
Therapeutic Opportunities on September 23-24 in Las Vegas, Nevada, and
the Society for Neuroscience on November 7-12 in Los Angeles,
California.
Copyright © 1998 PRNewswire.
--
Judith Richards, London, Ontario, Canada
[log in to unmask]
^^^
\ /
\ | / Today’s Research
\\ | // ...Tomorrow’s Cure
\ | /
\|/
